OncoMatch

OncoMatch/Clinical Trials/NCT06552260

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Is NCT06552260 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Troriluzole for glioblastoma.

Early Phase 1RecruitingUgonma ChukwuekeNCT06552260Data as of May 2026

Treatment: TroriluzoleThis research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Biomarker criteria

Required: IDH1 wild-type

Required: IDH2 wild-type

Disease stage

Required: Stage WHO GRADE 4 (WHO 2021)

Grade: 4 (WHO)

WHO Grade 4, and variants including gliosarcoma as per WHO 2021 criteria; Confirmed measurable disease per RANO 2.0 for GBM

Prior therapy

Max 2 prior lines
Min 1 prior line

Must have received: radiation therapy

Prior treatment with radiotherapy with or without chemotherapy.

Cannot have received: troriluzole (troriluzole)

Prior treatment with troriluzole or riluzole

Cannot have received: riluzole (riluzole)

Prior treatment with troriluzole or riluzole

Lab requirements

Blood counts

ANC ≥ 1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL

Kidney function

Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min

Liver function

Total bilirubin ≤ 2 × ULN (unless Gilbert's Syndrome, then < 5 mg/dL); AST/ALT ≤ 1.5 × ULN

Cardiac function

NYHA Functional Classification 2B or better

Laboratory values at the Screening Visit: ANC count < 1,500/mm3; Platelets <100,000/mm3; Hemoglobin < 9 g/dL; Total bilirubin > 2 × ULN (unless Gilbert's Syndrome, then < 5 mg/dL); AST > 1.5 x ULN; ALT > 1.5 x ULN; Serum creatinine > 1.5 mg/dL or creatinine clearance < 60 mL/min. Cardiac: NYHA Functional Classification 2B or better.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Brigham and Women's Hospital · Boston, Massachusetts
  • Dana-Farber Cancer Institute · Boston, Massachusetts
  • Massachusetts General Hospital Cancer Center · Boston, Massachusetts

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify